Sign in
Taking people in United StatesPhase 4

FES PET/CT brain scans for breast cancer spread to the brain

Tests FES brain scans in breast cancer that reached the brain.

Key facts

Who runs it
Weill Medical College of Cornell University
Where
New York, United StatesSee the site
Trial code
Registry title
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
Status
Recruiting
Phase
Phase 4
People taking part
20 people, planned
Started
27 Dec 2023
Expected to end
Dec 2027
Type of study
Interventional
Treatments tested
  • Brain Imaging with 18F-FES
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with ER-positive breast cancer that has spread to the brain, who are planned for radiation to the brain. They will have an extra 18F-FES PET/CT brain scan.

Age
18 years or older
Sex
Women only
Disease stage
Active ER+ breast cancer confirmed by biopsy, with new or returning brain metastases (cancer spread to the brain), proven by biopsy or suspected on MRI. Daily activity score (ECOG) 0-1. Expected to live at least 6 months.
Earlier treatment
ER modulators must be stopped for at least 8 weeks, and ER down regulators for at least 28 weeks. Radiation to the brain metastases must be planned.
Biomarker or test result
Estrogen receptor positive (ER+) breast cancer

Main reasons for not taking part

  • Pregnancy
  • Unable to have standard of care
  • Allergy to FES

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Active diagnosis of ER+ breast cancer (biopsy proven) and new or recurrent brain metastases (biopsy proven or suspected based on MRI appearance)
  • Ability to provide informed consent
  • Discontinuation of ER modulators for at least 8 weeks, and discontinuation of ER down regulators for at least 28 weeks (as per manufacturer guidelines)
  • Age >=18 years
  • Eastern Cooperative Oncology Group performance score 0-1
  • Life expectancy >=6 months
  • Planned for radiation treatment for brain metastases

Who cannot take part

  • Allergy to FES
  • Pregnancy
  • Unable to undergo Standard of Care

This trial is currently available in United States.

  • New York - Presbyterian - Weill Cornell Medical CenterNew York, United StatesContact: Jana Ivanidze, MD/PhDTaking people

About the trial

What the trial wants to find out

The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months.

Read full original descriptionShow less

Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.

The group in the trial

  • ER Positive Breast Cancer Patients with Brain MetastasesTreatment being tested

    A diagnostic intervention where this group will undergo an additional 18F- FES PET/CT scan in addition to their standard of care MRI and FDG PET/CT scan.

    Treatment: Brain Imaging with 18F-FES

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer
Plain-language title
FES PET/CT brain scans for breast cancer spread to the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
29 October 2026